Dictionnaire français - anglais

Participants were randomly selected to receive either teplizumab intravenously or a placebo for two weeks.

The rate of diagnosis of type 1 diabetes was 14.9% per year in the teplizumab group and 35.9% per year in the placebo group.

Annualised rates of diabetes were 14.9% for teplizumab group and 35.9% for placebo group

The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group.

Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed.